Bijuva is a combination drug containing two active ingredients: a conjugated estrogen and progesterone [1]. Specifically, the conjugated estrogen component is 0.5 mg, and the progesterone component is 100 mg [1].
What is the purpose of Bijuva?
Bijuva is prescribed for moderate to severe symptoms of vulvar and vaginal atrophy (VVA) due to menopause [1]. It is also used for women who have a uterus to reduce the risk of endometrial hyperplasia [1].
How does Bijuva work?
The conjugated estrogen in Bijuva provides estrogen to the body, which helps to alleviate menopausal symptoms like vaginal dryness and thinning [1]. The progesterone works to protect the lining of the uterus from overgrowth, known as endometrial hyperplasia, which can be caused by estrogen alone [1].
What are the alternative treatments for menopausal symptoms?
For women with a uterus, hormone therapy typically involves a combination of estrogen and progesterone to manage menopausal symptoms and protect the endometrium [2]. Other treatment options include non-hormonal medications, vaginal moisturizers, and lubricants [2].
When does Bijuva's patent protection end?
Information regarding the specific patent expiry dates for Bijuva is available through drug patent tracking resources [3]. DrugPatentWatch.com tracks patent information for various medications, including Bijuva [3].
Who manufactures Bijuva?
Bijuva is manufactured by Theramex [1].
What are the potential side effects of Bijuva?
Common side effects of Bijuva can include breast pain, vaginal bleeding, vaginal discharge, and headaches [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
What are the risks associated with Bijuva?
Like other estrogen-plus-progestin hormone therapies, Bijuva carries certain risks. These include an increased risk of heart attack, stroke, blood clots, and certain types of cancer, such as breast cancer and endometrial cancer [1]. Patients should consult their doctor to determine if the benefits of Bijuva outweigh these risks [1].
Are there any contraindications for using Bijuva?
Bijuva should not be used by individuals who have unexplained vaginal bleeding, have or have had breast cancer or other estrogen- or progestin-sensitive cancer, have or have had blood clots, have active arterial thromboembolic disease, or have known protein C, protein S, antithrombin, or other known thrombophilic disorders [1]. It is also not recommended for use in pregnancy [1].
What clinical data supports Bijuva's use?
Clinical studies have demonstrated that Bijuva effectively reduces moderate to severe hot flashes and vaginal dryness in postmenopausal women [1]. Further details on clinical trial outcomes and data can be found in the drug's prescribing information [1].
*
**Sources:
1. Bijuva Prescribing Information, Upsher-Smith Laboratories, LLC.
2. Mayo Clinic. (n.d.). Hormone therapy for menopause. Retrieved from https://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-therapy/art-20046372
3. DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/